

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Touyun Biotech Group Limited
透雲生物科技集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Touyun Biotech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, with effect from 3 August 2026, Ms. Zhou Ruijuan (“**Ms. Zhou**”) has been appointed as an executive director and vice chairlady of the Company, responsible for overseeing the Company’s new materials business development..

The biographical details of Ms. Zhou are set out below:

Ms. Zhou, aged 43, holds a Bachelor’s degree in Management from Lanzhou University. She has over 10 years of senior management experience in the technology and data services sectors. She serves as a director of certain subsidiaries of the Group.

Ms. Zhou was a founder and chairlady of 融合時代(重慶)新材料科技有限公司 (Ronghe Times (Chongqing) New Materials Technology Co., Ltd.*), one of the subsidiaries of the Group, she has been responsible for the company’s strategic planning, team building and business development since March 2025. From July 2020 to March 2024, she served as the general manager of 重慶海量互聯技術有限公司 (Chongqing Hailiang Interconnection Technology Co., Ltd.*), responsible for the expansion and implementation of the domestic database business in Southwest China. From June 2014 to January 2020, she served as a general Manager of 大衍(北京)科技有限公司 (Dayan (Beijing) Technology Co., Ltd.*), responsible for nationwide business development.

Ms. Zhou has entered into a service contract with the Company for a period of three years commencing from 3 August 2026, which may be terminated by either party giving one-month’s prior written notice. Her appointment is subject to retirement by rotation and re-election at the next following annual general meeting of the Company under the bye-laws of the Company. Ms. Zhou is entitled to a director’s fee of HK\$100,000 per month, which is determined by the remuneration committee of the Board and the Board on the basis of her experience, knowledge, qualifications, duties and responsibilities and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Ms. Zhou: (i) did not have any other relationship with any other director, senior management or substantial or controlling shareholders of the Company (within the definition of the Listing Rules); (ii) did not have any interest in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance; (iii) did not hold any other position with any member of the Group; (iv) had not held any directorship in any other companies listed in Hong Kong or overseas in the last three years; (v) had no other major appointment or professional qualification; and (vi) had no other information that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules nor any other matter that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to welcome Ms. Zhou for joining the Board.

* *for translation purpose only.*

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 3 August 2026

As at the date of this announcement, the Board comprises the following directors:

Executive Directors

Mr. Wang Liang (*Chairman*)
Ms. Zhou Ruijuan (*Vice chairlady*)
Mr. Du Dong

Non-executive Directors

Mr. Chen Hui
Ms. Tian Yuze
Mr. Zhang Lele

Independent Non-executive Directors

Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen